|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500106687 |
|
最近更新日期: Date of Last Refreshed on: |
2025-07-28 17:06:34 |
|
注册时间: Date of Registration: |
2025-07-28 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
分级运动康复在AECOPD患者氧化应激水平与膈肌功能中的作用研究 |
|
Public title: |
The role of graded exercise rehabilitation in the oxidative stress levels and diaphragmatic function of patients with AECOPD |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
分级运动康复在AECOPD患者氧化应激水平与膈肌功能中的作用研究 |
|
Scientific title: |
The role of graded exercise rehabilitation in the oxidative stress levels and diaphragmatic function of patients with AECOPD |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
冉宏敏 |
研究负责人: |
冉宏敏 |
|
Applicant: |
Hongmin Ran |
Study leader: |
Hongmin Ran |
|
申请注册联系人电话: Applicant telephone: |
+86 186 8566 4317 |
研究负责人电话:
Study leader's |
+86 186 8566 4317 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
18685664317@163.com |
研究负责人电子邮件: Study leader's E-mail: |
18685664317@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
贵州省遵义市红花岗区大学路1号 |
研究负责人通讯地址: |
遵义市新蒲新区新龙大道与新蒲大道交汇处 |
|
Applicant address: |
No. 1, Daxue Road, Honghuagang District, Zunyi City, Guizhou Province |
Study leader's address: |
No. 1, Daxue Road, Honghuagang District, Zunyi City, Guizhou Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
遵义医科大学 |
||
|
Applicant's institution: |
Zunyi Medical University |
||
|
研究负责人所在单位: |
遵义医科大学第二附属医院 |
||
|
Affiliation of the Leader: |
The Second Affiliated Hospital of Zunyi Medical University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
YXLL-2025-040 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
遵义医科大学第二附属医院伦理审查委员会 |
||
|
Name of the ethic committee: |
Ethics Review Committee of the Second Affiliated Hospital of Zunyi Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-04-04 00:00:00 | ||
|
伦理委员会联系人: |
巩亮 |
||
|
Contact Name of the ethic committee: |
Liang Gong |
||
|
伦理委员会联系地址: |
遵义市新蒲新区新龙大道与新蒲大道交汇处 |
||
|
Contact Address of the ethic committee: |
Intersection of Xinlong Avenue and Xinpu Avenue, Xinpu New District, Zunyi City |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 27596549 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
遵义医科大学第二附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Second Affiliated Hospital of Zunyi Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
遵义市新蒲新区新龙大道与新蒲大道交汇处 |
||||||||||||||||||||||
|
Primary sponsor's address: |
Intersection of Xinlong Avenue and Xinpu Avenue, Xinpu New District, Zunyi City |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
贵州省科学技术厅:黔科合成果-LC[2024]035 |
||||||||||||||||||||||
|
Source(s) of funding: |
Guizhou Provincial Department of Science and Technology: Qiankehe Achievements - LC[2024]035 |
||||||||||||||||||||||
|
研究疾病: |
慢性阻塞性肺疾病急性加重期 |
||||||||||||||||||||||
|
Target disease: |
acute exacerbation chronic obstructive pulmonary disease |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
1.探究分级运动康复、氧化应激水平和膈肌功能变化三者之间的内在相关性。 2.分析氧化应激水平、膈肌功能变化与AECOPD患者肺功能、运动耐力与生活质量等临床症状之间的关联性。 |
||||||||||||||||||||||
|
Objectives of Study: |
1. Investigate the intrinsic correlation between graded exercise rehabilitation, oxidative stress levels, and diaphragmatic function changes. 2. Analyze the correlation between oxidative stress levels, diaphragmatic function changes, and clinical symptoms such as lung function, exercise endurance, and quality of life in patients with AECOPD. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1、根据GOLD(Global Initiative for Chronic Obstructive Lung Disease,慢阻肺全球倡议)2024版中COPD的诊断标准,且病情处于急性加重期; 2、满足2022年EXODUS(EXpert consensus On Diaphragm Ultra Sonography in the critically ill,重症膈肌超声检测专家共识)膈肌移动度<2cm,膈肌厚度<2.2mm,膈肌增厚分数<20%中任意一项; 3、年龄在40~80岁; 4、意识清楚、语言交流无障碍并愿意配合本次研究者。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. According to the diagnostic criteria for COPD in the 2024 edition of GOLD (Global Initiative for Chronic Obstructive Lung Disease), and the condition is in an acute exacerbation phase; 2. Meets any one of the following criteria from the 2022 EXODUS (EXpert consensus On Diaphragm Ultra Sonography in the critically ill) guidelines: diaphragm mobility <2 cm, diaphragm thickness <2.2 mm, or diaphragm thickening fraction <20%; 3 Age between 40 and 80 years; 4.Be conscious, able to communicate verbally without difficulty, and willing to cooperate with the study. |
||||||||||||||||||||||
|
排除标准: |
1、存在运动禁忌症:未控制的高血压(>180/110 mmHg)与低血压(<90/60 mmHg);严重的心血管疾病;合并有支气管哮喘急性发作、肺栓塞、气胸等;存在影响运动神经肌肉疾病、骨关节病变等。 2、胸部畸形,已知的膈肌麻痹或慢性神经肌肉疾病; 3、研究过程中依从性差,不愿配合完成相关项目检查与干预。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Existence of contraindications for exercise: uncontrolled hypertension (>180/110 mmHg) and hypotension (<90/60 mmHg); severe cardiovascular disease; concomitant acute exacerbation of bronchial asthma, pulmonary embolism, pneumothorax, etc.; presence of conditions affecting neuromuscular diseases, osteoarthritis, etc. 2. Chest deformities, known diaphragmatic paralysis, or chronic neuromuscular diseases; 3. Poor compliance during the study, unwillingness to cooperate with relevant examinations and interventions. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-08-01 00:00:00至 To 2026-04-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-08-01 00:00:00 至 To 2026-04-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
采用前瞻性研究方法,首先根据表1的分级标准,对AECOPD患者进行仔细评估,并明确将其分为I级、II级和III级三个不同的级别。再使用随机数字表法,随机过程不受任何人的干预,将每一级别的患者随机分为研究组(A组)和对照组(B组)。本研究使用单盲法,确保患者不知道自己被分配到研究组还是对照组。根据患者的分级结果,将A组和B组内的患者分别细分为IA、IIA、IIIA和IB、IIB、IIIB六个亚组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Using a prospective research method, first, based on the grading criteria in Table 1, a detailed assessment was conducted on patients with AECOPD, and they were clearly classified into three different levels: I, II, and III. Then, using the random number table method, a random process was carried out without any intervention from anyone, and patients of each level were randomly divided into the study group (Group A) and the control group (Group B). This study employed a single-blind method to ensure that patients did not know which group they were assigned to (the study group or the control group). Based on the grading results of the patients, the patients in Group A and Group B were further divided into six subgroups: IA, IIA, IIAA, IIB, IIBA, and IIBIA. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
本研究使用单盲法,确保患者不知道自己被分配到研究组还是对照组。 |
|
Blinding: |
This study employed a single-blind method to ensure that patients did not know which group they were assigned to (the study group or the control group). |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
自2026年5月起,研究原始数据将通过加密EDC系统或邮箱18685664317@163.com |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Starting from May 2026, the original research data will be transmitted through the encrypted EDC system or the email address 1586828908@qq.com |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集和管理依托病例记录表(CRF)实现标准化纸质或电子化数据记录,并通过电子采集和管理系统(EDC,如ResMan)完成高效、准确的电子化数据录入、验证、存储与实时管理。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data collection and management are achieved through standardized paper or electronic data recording based on case record forms (CRF), and are completed through an electronic collection and management system (EDC, such as ResMan) for efficient, accurate electronic data entry, verification, storage and real-time management. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |